ELISA (recommended work dilution= 1:160,000 (at least detecting 6.25 µg/ml))
Immunogen was synthetic peptide derived from the near N-terminus of human Endoglin. This antibody was produced from a rabbit immunized with the immunogen. The IgG fraction was purified from rabbit serum by ammonium sulphate precipitation, and followed by Protein A/G affinity chromatography.
A separate vial of dilution buffer is provided for reconstitution. The antibody is supplied lyophilized, originally containing PBS, without preservative stabilizers (e.g. sodium azide). The final amount is indicated on the shipping vial.
Endoglin. also known as CD105, is a type I membrane glycoprotein located on cell surfaces and is part of the TGF beta receptor complex. It is involved in the binding of TGF-beta1, TGF-beta3, activin-A, BMP-2, and BMP-7. Beside TGF-beta signaling, endoglin has other functions, such as affecting cell morphology and migration. Endoglin has a role in the development of the cardiovascular system and in vascular remodeling. Its expression is regulated during heart development.
The antibody is stable for at least 1 year from the date of receipt when stored at -20°C to -70°C. Reconstituted antibody can also be aliquotted and stored at 4°C for 1 month or at -20°C to -70°C in a manual defrost freezer for many months without detectable loss activity. Please avoid freeze-thaw cycles.
The antibody can specifically bind to its immunogen, and did not show any cross reactivity with unrelated antigens in ELISA. The specificity for binding to recombinant protein, cellular protein and native antigen is not defined. Cross reactivity with mouse and rat Endoglin has not yet been tested.
Human Endoglin ELISA Kit (Cat# ELH-Endoglin-001 )Rabbit Anti-Endoglin antibody-C-terminus(Cat# 130-10021)Recombinant Human Endoglin (Cat# 228-10387)
- ten Dijke P, Goumans MJ, Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis. 2008;11(1):79-89.
- Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ, Ellis LM. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res. 2008 Apr 1;14(7):1931-7.